Triple
T23186623
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | REGN |
E579608
|
entity |
| Predicate | hasUnderlyingCompanyTechnologyPlatform |
P82035
|
FINISHED |
| Object | VelocImmune antibody technology |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: VelocImmune antibody technology | Statement: [REGN, hasUnderlyingCompanyTechnologyPlatform, VelocImmune antibody technology]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: VelocImmune antibody technology Context triple: [REGN, hasUnderlyingCompanyTechnologyPlatform, VelocImmune antibody technology]
-
A.
VelocImmune technology
chosen
VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
-
B.
HyperAcute cellular immunotherapy platform
HyperAcute cellular immunotherapy platform is a cancer treatment technology that uses genetically modified tumor cells to stimulate a strong immune response against cancer.
-
C.
DxI immunoassay systems
DxI immunoassay systems are automated laboratory analyzers used for high-throughput, chemiluminescent immunoassay testing in clinical diagnostics.
-
D.
Semple-type rabies vaccine
The Semple-type rabies vaccine is an early nerve-tissue–based rabies vaccine developed by British bacteriologist David Semple, historically used for post-exposure prophylaxis before modern cell-culture vaccines became standard.
-
E.
Cambridge Antibody Technology
Cambridge Antibody Technology was a pioneering UK biotechnology company best known for developing human monoclonal antibody technologies that led to blockbuster therapeutic drugs.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: hasUnderlyingCompanyTechnologyPlatform Context triple: [REGN, hasUnderlyingCompanyTechnologyPlatform, VelocImmune antibody technology]
-
A.
underlyingCompanyKeyTechnology
chosen
Indicates that a specific technology serves as a core or foundational technological component for a given company.
-
B.
hasUnderlyingCompanyBusinessModel
Indicates that one entity possesses or is based on a specific company business model that underlies its structure, operations, or value creation.
-
C.
hasUnderlyingCompanyMainProductType
Indicates that an entity’s primary product type is based on or derived from the main product type of an associated underlying company.
-
D.
hasUnderlyingCompanyOperationsIn
Indicates that a company’s core or foundational business activities take place within a specified geographic location or jurisdiction.
-
E.
hasUnderlyingCompanyBrand
Indicates that one entity is associated with or operates under the corporate brand of another company as its underlying brand.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e245ff8000819090d12008805315b7 |
completed | April 17, 2026, 2:38 p.m. |
| NER | Named-entity recognition | batch_69f18fd3aaa08190b9cf7afe4ee5a38d |
completed | April 29, 2026, 4:57 a.m. |
| PD | Predicate disambiguation | batch_69ef8a041c0081909afb670d17a5aaba |
completed | April 27, 2026, 4:08 p.m. |
Created at: April 17, 2026, 4:05 p.m.